19.10.2015 - US drug maker Eli Lilly has discontinued clinical trials with evacetrapib, a potential blockbuster medicine it had hoped to recommend for treatment of high-risk atherosclerotic...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)